Woodgate Derek E, Conquer Julie A
NxCare Inc., Guelph, Ontario, Canada, and the Departments of ; Human Biology and Nutritional Sciences and.
Human Nutraceutical Research Unit, University of Guelph, Guelph, Ontario, Canada.
Curr Ther Res Clin Exp. 2003 Apr;64(4):248-62. doi: 10.1016/S0011-393X(03)00058-4.
Obesity is a well-established risk factor for cardiovascular disease, diabetes, hyperlipidemia, hypertension, osteoarthritis, and stroke. Stimulants, such as ephedrine and caffeine and their herbal counterparts, have proved effective in facilitating body weight loss, but their use is controversial due to their undesired effects. Other nutraceuticals have shown moderate success in reducing body weight, whereas several other compounds have demonstrated little or no effect. Therefore, a tolerable and effective nutraceutical that can increase energy expenditure and/or decrease caloric intake is desirable for body weight reduction.
The primary purpose of this study was to assess the tolerability and effectiveness of a novel, stimulant-free, dietary supplement containing glucomannan, chitosan, fenugreek, Gymnema sylvestre, and vitamin C on body weight and fat loss and change in body composition in obese adults.
In this single-center, prospective, randomized, double-blind, placebo-controlled study conducted at the University of Guelph (Guelph, Ontario, Canada), obese adults (aged 20-50 years; body mass index [BMI], ≥30 kg/m(2)) were randomized to the treatment or placebo group. The treatment group received 6 capsules of a dietary supplement containing a proprietary blend of glucomannan, chitosan, fenugreek, G sylvestre, and vitamin C daily for 6 weeks, and the placebo group received 6 capsules of rice flour daily for 6 weeks. Body weight; percentage of body fat; absolute fat mass; lean body mass; BMI; upper abdominal, waist, and hip circumference; and anthropometric measurements were recorded at baseline and at study end. Patients completed daily dietary intake records on days 1 to 3 and days 40 to 42. They also completed weekly activity logs throughout the study.
Twenty-four subjects (mean [SD] age, 37.0 [8.2] years [range, 21-48years]; mean [SD] BMI, 35.7 [6.2] kg/m(2) [range, 28.9-50.9 kg/m(2)]) were assigned to the treatment group (8 women, 4 men) or the placebo group (9 women,3 men). Two subjects (8.3%; 1 patient [8.3%] from each group) dropped out for personal reasons unrelated to the study. No significant changes in the consumption of total calories; the percentage of calories ingested as carbohydrates, fat, or protein; or activity levels were found in either group throughout the study. Compared with the placebo group, the treatment group lost significantly more body weight (-2.3 kg vs 0.0 kg; P<0.01), percentage of body fat (-1.1% vs 0.2%; P<0.05), and absolute fat mass (-2.0 kg vs 0.2 kg; P<0.001). The treatment group also experienced a significantly greater reduction in upper abdominal circumference (-4.5 cm vs -0.7 cm), waist circumference (-4.1 cm vs 0.1 cm), and hip circumference (-2.9 cm vs 0.6 cm) compared with the placebo group (P<0.05 for all). No significant changes in heart rate or blood pressure were found in either group. Both the treatment and the placebo were well tolerated.
Within the context of this study, the novel combination of glucomannan, chitosan, fenugreek, G sylvestre, and vitamin C results in significant body weight and fat loss in obese adults. Disclosure: Derek E. Woodgate, MSc, is president and owner of NxCare Inc., which produces the dietary supplement containing glucomannan, chitosan, fenugreek, Gymnema sylvestre, and vitamin C (trade name Calorie-Care™).
肥胖是心血管疾病、糖尿病、高脂血症、高血压、骨关节炎和中风的公认危险因素。麻黄碱、咖啡因等兴奋剂及其草药同类物已被证明在促进体重减轻方面有效,但由于其不良作用,其使用存在争议。其他营养保健品在减轻体重方面取得了一定成功,而其他几种化合物则几乎没有效果或没有效果。因此,一种可耐受且有效的营养保健品,能够增加能量消耗和/或减少热量摄入,对于减轻体重是可取的。
本研究的主要目的是评估一种新型、无兴奋剂的膳食补充剂(含有葡甘露聚糖、壳聚糖、葫芦巴、匙羹藤和维生素C)对肥胖成年人的体重、脂肪减少及身体成分变化的耐受性和有效性。
在加拿大安大略省圭尔夫大学进行的这项单中心、前瞻性、随机、双盲、安慰剂对照研究中,肥胖成年人(年龄20 - 50岁;体重指数[BMI]≥30 kg/m²)被随机分为治疗组或安慰剂组。治疗组每天服用6粒含有葡甘露聚糖、壳聚糖、葫芦巴、匙羹藤和维生素C专利配方的膳食补充剂,持续6周,安慰剂组每天服用6粒米粉,持续6周。在基线和研究结束时记录体重、体脂百分比、绝对脂肪量、瘦体重、BMI、上腹部、腰围和臀围以及人体测量数据。患者在第1至3天和第40至42天完成每日饮食摄入记录。他们在整个研究过程中还完成每周的活动日志。
24名受试者(平均[标准差]年龄37.0[8.2]岁[范围21 - 48岁];平均[标准差]BMI 35.7[6.2]kg/m²[范围28.9 - 50.